Women’s Special Issue Series: Pharmacoepidemiology
A special issue of Pharmacoepidemiology (ISSN 2813-0618).
Deadline for manuscript submissions: 31 October 2025 | Viewed by 159
Special Issue Editors
Interests: pharmacoepidemiology; appropriateness of drug prescription; drug safety; medication adherence; geriatric pharmacology; nutrition; educational randomized controlled trials
Special Issues, Collections and Topics in MDPI journals
Interests: drug utilisation research; medication safety; medication adherence; deprescribing; prescribing indicators; optimising opioids and chronic pain; adherence to oral systemic anti-cancer therapy
2. Population Health and Best Health Practices Research Group, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
3. Faculty of Pharmacy, Université Laval, Québec, QC, Canada
Interests: pharmacoepidemiology; drug utilization research; medication adherence; medication persistence; administrative databases; mental health epidemiology; polypharmacy; multimorbidity; environmental impact of medications
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a Special Issue entitled “Women’s Special Issue Series: Pharmacoepidemiology” to celebrate and highlight the achievements of women in the development of pharmacoepidemiology, the key research area spanning clinical pharmacology and epidemiology.
For this Special Issue, we invite submissions of original research articles and comprehensive review papers including, but not limited to, the following topics:
- Designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
- Molecular pharmacoepidemiology;
- The methodology of pharmacoepidemiology;
- Pharmacovigilance/preventative pharmacovigilance/ecopharmacovigilance;
- Patient safety;
- Pharmacoepidemiology studies in targeted populations and settings;
- Patterns in drug utilization;
- Patterns in drug prescription, the appropriateness of prescriptions, and overprescription;
- Polypharmacology;
- Randomized controlled drug trials;
- Systematic reviews or meta-analyses related to drugs;
- Post-marketing surveillance;
- Pharmacoeconomics;
- The formulation and interpretation of regulatory guidelines;
- Studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
- Harm/benefit assessments in drug therapy;
- The evaluation of risk management plans for pharmaceuticals, biologics, and medical devices.
We look forward to receiving your contributions.
Dr. Carlotta Franchi
Prof. Dr. Li-Chia Chen
Dr. Carlotta Lunghi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacoepidemiology is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacoepidemiology
- pharmacovigilance
- preventative pharmacovigilance
- ecopharmacovigilance
- patient safety
- patterns in drug utilization
- polypharmacology
- randomized controlled drug trials
- post-marketing surveillance
- pharmacoeconomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.